Update on Aspirin Desensitization for Chronic Rhinosinusitis with Polyps in Aspirin-Exacerbated Respiratory Disease (AERD)

详细信息    查看全文

• 作者：Ronald A. Simon (1)
  Kristen M. Dazy (1)
  Jeremy D. Waldram (1)
  
  1. Division of Allergy ; Asthma and Immunology ; Scripps Clinic ; 3811 Valley Centre Drive ; San Diego ; CA ; 92130 ; USA
  
• 关键词：Aspirin ; exacerbated respiratory disease ; Samter鈥檚 triad ; Aspirin desensitization ; Aspirin intolerance ; Nasal polyps ; Asthma
• 刊名：Current Allergy and Asthma Reports
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：15
• 期：3
• 全文大小：1,002 KB
• 参考文献：1. Szczeklik A, Nizankowska-Mogilnicka E, Sanak M. Hypersensitivity to aspirin and non-steroidal anti-inflammatory drugs. In: Adkinson Jr NF, Bochner BS, Busse WW, Holgate ST, Lemanske Jr RF, Simons FER, editors. Middleton鈥檚 allergy: principles and practice. 7th ed. New York: Mosby; 2009. p. 1227鈥?0. CrossRef
  2. Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin N Am. 2004;24:491鈥?05. CrossRef
  3. Woessner KM, White AA. Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2014;133(1):286鈥?. / e1-9. CrossRef
  4. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002;89:474鈥?. CrossRef
  5. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis, and chronic obstructive pulmonary disease in a population based study. Int J Epidemiol. 1999;28:717鈥?2. CrossRef
  6. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax. 2002;57:569鈥?4. CrossRef
  7. Weber RW, Hoffman M, Raine Jr DA, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol. 1979;64:32鈥?. CrossRef
  8. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328:434. CrossRef
  9. Stevenson DD, Simon RA, Zuraw BL. Sensitivity to aspirin and NSAIDs. In: Adkinson NJ, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simon FE, editors. Middleton: allergy principles and practice, vol. 2. 6th ed. Philadelphia: CV Mosby and Co; 2003. p. 1965鈥?10.
  10. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62:1111鈥?. CrossRef
  11. Widal MF, Abrami P, Lermeyez J. Idiosyncratic anaphylaxis. Presse Med. 1922;30:189鈥?2.
  12. Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep. 2009;9:155鈥?3. CrossRef
  13. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006;118:773鈥?8. CrossRef
  14. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med. 2002;166:301鈥?. CrossRef
  15. Kowalski ML, Pawliczak R, Wozniak J, Siuda K, Poniatowska M, Iwaszkiewicz J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med. 2000;161:391鈥?. CrossRef
  16. Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, Cohn J, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol. 1994;94:1046鈥?6. CrossRef
  17. Liu T, Laidlaw TM, Katz HR, Boyce JA. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A. 2013;110:16987鈥?2. CrossRef
  18. Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol. 2003;24:159鈥?8. CrossRef
  19. Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol. 2008;100:420鈥?. CrossRef
  20. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 2002;46:2201鈥?. CrossRef
  21. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol. 2001;108:47鈥?1. CrossRef
  22. Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, et al. Biochemical and clinical evidence that aspirin-intolerance asthmatic subjects tolerate the cyclooxygenase-2-selective analgetic drug celecoxib. J Allergy Clin Immunol. 2003;111:1116鈥?1. CrossRef
  23. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111:180鈥?. CrossRef
  24. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long term outcomes. J Allergy Clin Immunol. 1996;98:751鈥?. CrossRef
  25. Shaker M, Lobb A, Jenkins P, O鈥橰ourke D, Takemoto SK, Sheth S, et al. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2008;121:81鈥?. CrossRef
  26. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med. 2002;347:1493鈥?. CrossRef
  27. Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2010;126:738鈥?4. CrossRef
  28. Steinke JW, Culp JA, Kropf E, Borish L. Modulation of aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol. 2009;124:724鈥?0. / e4. CrossRef
  29. Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006;118:801鈥?. CrossRef
  30. Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98:172鈥?. CrossRef
  31. Dahlen B. Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Respir Crit Care Med. 2006;161(Suppl):S137鈥?1.
  32. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy. 2002;32:1491鈥?. CrossRef
  33. White A, Ludington E, Mehra P, Steventon DD, Simon RA. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol. 2006;97:688鈥?3. CrossRef
  34. Hope AP, Woessner KA, Simon RA, Stevenson DD. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2009;123:406鈥?0. CrossRef
  35. Lee RU, White AA, Ding D, Dursun AB, Woessner KM, Simon RA, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2010;105:130鈥?. CrossRef
  36. White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2006;97:190鈥?. CrossRef
  37. Williams AN, Simon RA, Woessner KM, Stevenson DD. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol. 2007;120:273鈥?. CrossRef
  38. White AA et al. The clinical dilemma of 鈥渟ilent desensitization鈥?in aspirin-exacerbated respiratory disease. Allergy Asthma Proc. 2013;34:378鈥?2. / Silent desensitization is an uncommon but important outcome to recognize. Clinicians performing aspirin desensitization in AERD patients should understand that this can occur and consider a second confirmatory aspirin challenge in some patients. CrossRef
  39. Stevenson DD, Pleskow WW, Simon RA, Mathison DA, Lumry WR, Schatz M, et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind cross-over study of treatment with aspirin. J Allergy Clin Immunol. 1984;73:500鈥?. CrossRef
  40. Gosepath J et al. Individual monitoring of aspirin desensitization. Arch Otolaryngol Head Neck Surg. 2001;127:316鈥?1. CrossRef
  41. Fruth K. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy. 2013;68(5):659鈥?5. / This study is important in the AERD literature because it is a randomized controlled trial, and there are very few such studies providing us with outcome data. The study was limited, however, by a high dropout rate. CrossRef
  42. Rozsasi et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300聽mg aspirin daily. Allergy. 2008;63:1228鈥?4. CrossRef
  43. Chiu JT. Improvement in aspirin-sensitive asthmatic subjects after rapid aspirin desensitization and aspirin maintenance (ADAM) treatment. J Allergy Clin Immunol. 1983;71:560鈥?. CrossRef
  44. Sweet JA, Stevenson DD, Simon RA, Mathison DA. Long term effects of aspirin desensitization treatment for aspirin sensitive rhinosinusitis asthma. J Allergy Clin Immunol. 1990;86:59鈥?5. CrossRef
  45. Comert et al. Aspirin 300聽mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy. 2013;68:1443鈥?1. CrossRef
  46. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2007;119:157鈥?4. CrossRef
  47. Slavin et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol. 2005;116:S16鈥?7. CrossRef
  48. Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol. 1980;66:82鈥?. CrossRef
  49. Berges-Gimeno P, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2003;90:338鈥?1. CrossRef
  50. McMains KC, Kountakis SE. Medical and surgical considerations in patients with Samter鈥檚 triad. Am J Rhinol. 2006;20:573鈥?. CrossRef
  51. Havel M et al. Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol. 2012;270(2):571鈥?. / This study had a relatively large number of patients and was thorough in its evaluation of outcomes. It is also clinically relevant as aspirin desensitization is commonly done in the weeks following sinus surgery, which is the type of patient they evaluated. CrossRef
  52. Cho et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151(4):575鈥?1. CrossRef
  53. Forer A et al. Aspirin desensitization for ASA triad patients鈥攑rospective study of the rhinologist鈥檚 perspective. Rhinology. 2011;49(1):95鈥?.
  54. Ogata A et al. Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol. 2007;121(12):1156鈥?0. CrossRef
  55. Parikh AA, Scadding GK. Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope. 2005;115(8):1385鈥?0. CrossRef
  
• 刊物主题：Allergology;
• 出版者：Springer US
• ISSN：1534-6315

文摘

Aspirin-exacerbated respiratory disease (AERD) is a clinical condition which results in adverse upper and lower respiratory symptoms, particularly rhinitis, conjunctivitis, bronchospasm, and/or laryngospasm, following exposure to cyclooxygenase-1 (COX-1) inhibiting drugs, namely aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs). A provocative aspirin challenge is the gold standard for diagnosis of AERD. Aspirin desensitization and continuous aspirin therapy has been highly efficacious in those patients with suboptimal control of their disease on current available pharmacotherapy or those with other underlying conditions (i.e., cardiovascular disease) who may require frequent treatment with aspirin or NSAIDs. This review article focuses on aspirin desensitization and the management of patients with AERD with a particular emphasis on outcomes in those patients with chronic rhinosinusitis and nasal polyposis.